Search Results - can+sarica

23 Results

Sort By:

Advantages Combines recording and stimulation in a single device Reduces brain penetration and surgery time Lowers risk of hemorrhage, infection, and brain shift Enables precise brain mapping and real-time stimulation Summary Deep Brain Stimulation (DBS) helps patients with movement disorders like Parkinson’s disease by sending electrical...

Published: 5/30/2025 | Inventor(s): Oliver Flouty, Yarema Bezchlibnyk, Vishal Bharmauria, Nour Shaheen, Brian Dalm, Can Sarica, Matthew Howard, Hiroto Kawasaki, Mario Zanaty, Alex Green, Andres Lozano

Keywords(s):

Category(s): Technology Classifications > Medical > Neuroscience

High-Potency Biased β2-adrenergic Receptor Agonist for Treating Respiratory Diseases

Advantages Ultra-potent β2-adrenergic receptor agonist that stimulates cAMP production with sub-nanomolar potency (EC50 = 0.25nM) Biased signaling profile selectively activates Gαs-mediated cAMP signaling while avoiding β-arrestin2 recruitment, reducing receptor desensitization characteristic of traditional treatments such as albuterol Maintains...

Published: 5/27/2025 | Inventor(s): Stephen Liggett, Donghwa Kim, Yu Chen, Jesper Madsen, Steven An

Keywords(s): Pharmaceuticals, Respiratory Diseases Treatment

Category(s): Technology Classifications > Medical > Respiratory, Technology Classifications > Medical > Therapeutics, Technology Classifications > Medical > Pharmaceuticals

S100A4 Monoclonal Antibody for Therapeutic and Diagnostic Use

Cancer metastasis are responsible for ~90% of cancer associated deaths. Recent studies suggest that immune cells play critical roles in promoting metastasis, especially myeloid cells from the bone marrow. UTHealth researchers, with researchers from Houston Methodist Hospital, observed a highly conserved expression of S100A4 in immune suppressive myeloid...

Published: 5/9/2025 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Oncology, Therapeutics

LILRB2 Monoclonal Antibody for Therapeutic and Diagnostic Uses of Neurodegenerative Diseases

Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. TREM2 signaling inhibition is mediated by leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). UTHealth inventors created and engineered...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Therapeutics

Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...

Published: 4/22/2025 | Inventor(s): Yves Pommier, Lin-kun An, Keli Agama, Evgeny Kiselev, Azhar Ravji

Keywords(s): Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...

Published: 3/24/2025 | Inventor(s): Zhiqiang An, Ningyan Zhang, Kathryn O'Donnell

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics, Biologics

A Potent Short Hairpin RNA (SHRNA734) to Positively Select and Eliminate Genetically Modified Cells (UCLA Case No. 2016-524)

BACKGROUND: Gene therapy strategies to modify human stem cells hold great promise for curing many human diseases. However, previous clinical studies have met with limited success, largely due to the low engraftment of gene modified stem cells. One strategy to overcome this challenge involves engineering stem cells in which HPRT expression is knocked...

Published: 3/6/2025 | Inventor(s): Dong Sung An, Saki Shimizu

Keywords(s):

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Infectious Diseases

Method for Dry Battery Electrode Manufacturing Via Direct Powder Bed Formation and Compression

Background Recent efforts to address climate change and develop a clean-energy economy in the United States have focused on the electrification of the transportation sector. Sustainable battery manufacturing has become a critical part of these efforts, and current manufacturing practices face challenges relating to environmental impact, advancing electrode...

Published: 2/13/2025 | Inventor(s): Yoon Hwa, Yuhui An

Keywords(s): Battery, Energy storage, Engineering, Manufacturing, Powder

Category(s): Physical Science, Energy & Power, Alternative Energy, Semiconductors, Materials & Processes

Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.

Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Monoclonal Antibodies Binding to Transferrin Receptor (TfR) for Therapeutic Protein Delivery across Blood-Brain Barrier

Blood-brain barrier (BBB) limits brain entry and is one of the major hurdles in developing antibody and protein-based therapeutics for central nervous system (CNS) diseases. UTHealth researchers identified and engineered monoclonal antibodies binding to transferrin receptor (TfR) but not affecting transferrin (Tf) binding to TfR. An engineered monovalent...

Published: 4/23/2025 | Inventor(s): Zhiqiang An

Keywords(s):

Category(s): Drug Delivery, Therapeutics, Neurology/Neurosurgery, Oncology, Biologics

1 2 3